drugset / Trial / NCT03163849

Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients

NCT03163849

Phase 3 Unknown 50 enrolled Assiut University
RandomizedParallel-groupOpen-labelTreatment

Summary

Chronic hepatitis C virus infection affects an estimated one hundred and seventy million people around the world with and approximate prevalence 0.2-2 % in the United State of America and European countries.

Timeline

Start
2019-09-01
Primary completion
2020-06-01
Completion
2020-07-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Daclatasvir Small molecule Oral
Subject Sofosbuvir Small molecule Oral